Kepsee - Meklēšanas rezultāti

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

xigris

eli lilly nederland b.v. - drotrecogin alfa (activated) - sepsis; multiple organ failure - antitrombotiskie līdzekļi - xigris tiek norādīts ārstēšana pieaugušiem pacientiem ar smagu sepse ar vairāku orgānu mazspēju, pievienojot standarta vislabāko iespējamo aprūpi. xigris lietošana galvenokārt jāņem vērā situācijās, kad terapiju var uzsākt 24 stundu laikā pēc orgānu mazspējas rašanās (plašāku informāciju skatīt apakšpunktā 5)..

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - hemoglobīnūrija, paroksizmāla - selective immunosuppressants - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.